VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2015 | HELIOS trial: Ibrutinib combined with BR for previously treated CLL/SLL

At the 20th Congress of the European Hematology Association (EHA), Paula Cramer, MD, of the University Hospital Cologne, Cologne, Germany, discusses the first results from the Phase III HELIOS trial, which evaluated the first-in-class, oral covalent Bruton’s tyrosine kinase inhibitor, ibrutinib, in combination with bendamustine and rituximab (BR) versus BR plus placebo in patients with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter